Scarica l'app Stockscreener
0.8899
0.45%
-0.004
Precedente Chiudi:
$0.8939
Aprire:
$0.88
Volume 24 ore:
252.99K
Relative Volume:
0.13
Capitalizzazione di mercato:
$67.24M
Reddito:
$361.07M
Utile/perdita netta:
$-71.54M
Rapporto P/E:
-1.1265
EPS:
-0.79
Flusso di cassa netto:
$-47.97M
1 W Prestazione:
-7.41%
1M Prestazione:
+48.74%
6M Prestazione:
+157.12%
1 anno Prestazione:
-51.64%
Intervallo 1D:
$0.88
$0.99
Intervallo di 1 settimana:
$0.88
$1.07
Portata 52W:
$0.1253
$2.10
Oncology Institute Inc Stock (TOI) Company Profile
Nome
Oncology Institute Inc
Settore
Industria
Telefono
562-735-3226
Indirizzo
18000 STUDEBAKER RD, CERRITOS
Confronta TOI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TOI
Oncology Institute Inc
|
0.8899 | 67.24M | 361.07M | -71.54M | -47.97M | -0.79 |
|
HCA
Hca Healthcare Inc
|
316.42 | 78.58B | 70.60B | 5.76B | 5.64B | 21.97 |
|
FMS
Fresenius Medical Care Ag Adr
|
23.09 | 13.55B | 20.87B | 715.14M | 1.67B | 1.2209 |
|
THC
Tenet Healthcare Corp
|
129.60 | 12.66B | 20.97B | 3.13B | 2.39B | 31.21 |
|
DVA
Davita Inc
|
142.40 | 12.49B | 12.67B | 827.68M | 1.42B | 9.27 |
|
UHS
Universal Health Services Inc
|
180.03 | 11.88B | 15.42B | 1.03B | 956.84M | 15.02 |
Oncology Institute Inc Stock (TOI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-26 | Ripresa | Jefferies | Buy |
| 2022-09-14 | Iniziato | Guggenheim | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
Oncology Institute Inc Borsa (TOI) Ultime notizie
Oncology Institute (NASDAQ:TOI) Stock Price Down 6.9%Time to Sell? - MarketBeat
A groundbreaking project at the Oncology Institute in Shaare Zedek Medical Center - The Jerusalem Post
In the Green: Oncology Institute Inc (TOI) Closes at 0.82, Up/Down -7.68 from Previous Day - The Dwinnex
Oncology Institute Inc [TOI] Investment Appeal on the Rise - Knox Daily
Market Insights: Oncology Institute Inc (TOI)’s Notable Drop of -3.75, Closing at 0.85 - The Dwinnex
Oncology Institute's Market Cap Up US$7.0m Following Year Of Insider Stock Buying - Yahoo Finance
Oncology Institute Inc (TOI) Stock: A Year of Market Fluctuations - The InvestChronicle
Oncology Institute Inc [TOI] Stock bought by Insider Hively Brad for $42500.0 - Knox Daily
The Oncology Institute Inc (TOI) had a good session last reading, didn’t it? - US Post News
Why The Oncology Institute (TOI) Is Skyrocketing So Far In 2025 - Insider Monkey
The Oncology Institute, Inc. (NASDAQ:TOI) Sees Large Growth in Short Interest - MarketBeat
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company - Simply Wall St
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection - Business Wire
Guardant Health's Shield Cancer Test Selected for Major NCI Study Covering 10 Cancer Types - StockTitan
The Oncology Institute Inc WT (TOIIW-Q) QuotePress Release - The Globe and Mail
HighTower Advisors LLC Has $27,000 Stock Position in The Oncology Institute, Inc. (NASDAQ:TOI) - Defense World
Oncology Institute faces potential Nasdaq delisting - Investing.com
Florida Blue enhances cancer care for thousands of members - The Manila Times
Florida Blue Launches Breakthrough Cancer Care Program with The Oncology Institute Partnership - StockTitan
Brian Druker resigns as OHSU Knight Cancer Institute CEO - Portland Business Journal
Oncology institute director Brad Hively acquires $50,000 in stock - Investing.com
Oncology institute director Brad Hively acquires $50,000 in stock By Investing.com - Investing.com UK
Tomorrow’s Promise, Today’s Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment - Roswell Park Comprehensive Cancer Center
2024 Face of Hope: Carolina BioOncology Institute - Charlotte magazine
Despite Recent Gains, Oncology Institute Insiders Are Still Down US$110k - Simply Wall St
Shuttle Pharma Expands Patient Enrollment for Phase 2 - GlobeNewswire
Grapevine Saves The Oncology Institute Millions On Healthcare Supplies - Markets Insider
Oncology Institute Inc (NASDAQ: TOI): Blank Check For Growth? - Stocks Register
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - The Manila Times
RenovoRx Expands Phase III Pancreatic Cancer Trial with Major Cancer Institute Partnership - StockTitan
Oncology Institute Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.19 loss in 3Q 2023) - Yahoo Finance
The Oncology Institute, Inc. (NASDAQ:TOI) Q3 2024 Earnings Call Transcript - Insider Monkey
USF and TGH partner with robotics company to become the first to bring life-saving surgical technology to Tampa Bay - University of South Florida
Earnings call: The Oncology Institute reports strong growth in Q3 2024 - Investing.com
Oncology Institute Reports Strong Revenue Growth Amid Challenges - TipRanks
The Oncology Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
The Oncology Institute Reports Third Quarter 2024 Financial Results - The Manila Times
Oncology Institute Q3 Revenue Jumps 22% to $99.9M Despite Margin Pressure | TOI Stock News - StockTitan
Oncology Institute Announces Board Changes for 2025 - TipRanks
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace
The Oncology Institute Announces Certification to Administer Pluvicto Therapy in California - The Manila Times
Oncology Institute (TOI) Launches Groundbreaking Outpatient Cancer Treatment Service | TOI Stock News - StockTitan
The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call - ForexTV.com
Cancer Care - WellSpan Health
Bayhealth welcomes new hematologist oncologist to cancer institute - CapeGazette.com
GlycoMimetics, Inc. Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Marketscreener.com
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire
Oncology Institute Inc Azioni (TOI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):